Filing Flows › Health Care › Longeveron (LGVN)
Longeveron (LGVN) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Longeveron (LGVN) Q2 2026 earnings results →
Q2 2026 Revenue down 9% year over year to $287K
Longeveron made $287K in Q2 2026 (-9% Y/Y). Operating margin n/m, net loss $6.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $287K in Q2 2026, down 9% year over year and down 28% from the previous quarter.
Gross margin was 63.4%, up 17.2 points from Q2 2025. Operating costs exceeded revenue by $6.2M, an operating margin of -2150.2%. Operating expenses grew 15% against a revenue fall of 9%. The fastest-growing cost line was General & admin (+22%). The quarter ended with a net loss of $6.1M, wider than the previous quarter's $4.7M loss.
Operating cash flow was −$5.7M. Non-cash charges added back $221K of depreciation and amortization and $373K of share-based compensation. Capital expenditures of $103K exceeded it, leaving free cash flow of −$5.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $287K | -9% | n/m | −$6.1M | −$5.7M |
| Q1 2026 | 10-Q | May 13, 2026 | $398K | +4% | n/m | −$4.7M | −$4.4M |
| Q4 2025 | 10-K | Mar 17, 2026 | $365K | -40% | n/m | −$5.4M | −$5.3M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $137K | -82% | n/m | −$7.2M | −$5.1M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $316K | -32% | n/m | −$5.0M | −$3.6M |
| Q1 2025 | 10-Q | May 8, 2025 | $381K | -30% | n/m | −$5.0M | −$4.7M |
| Q4 2024 | 10-K | Feb 28, 2025 | $603K | +857% | -710.0% | −$4.1M | −$3.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Longeveron
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B ® ), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important U.S.
In its own words, from its 8-K, filed Aug 12, 2026.
Longeveron against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -9% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LGVN Longeveron | Q2 2026 | $287K | -9% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Longeveron 10-Q on SEC EDGAR · CIK 1721484 · Pharmaceutical Preparations
More on LGVN
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results